Anurag Mehta1,2, Prerna Chadha3, Poojan Agarwal1, Sunil Pasricha1. 1. Department of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085, India. 2. Department of Research, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India. 3. Department of Laboratory and Transfusion Services, Rajiv Gandhi Cancer Institute & Research Centre, Sector 5, Rohini, Delhi, 110085, India. chadha.prerna@gmail.com.
Abstract
BACKGROUND: Aberrant T cell antigen expression has been well documented in diffuse large B cell lymphomas. However, co-expression of multiple T cell antigens including CD3, which has been considered a specific marker for T cells is extremely rare. Awareness about such aberrant expression is important so as not to misdiagnose or wrongly classify a lymphoma. The aim of this article is to report such a case. CASE PRESENTATION: A 68-year-old postmenopausal lady, diabetic and hypertensive, presented with an axillary lump of one week's duration. There was no other relevant medical history. Ultrasonography revealed multiple hypoechoic cystic lesions varying in size from 3.9 to 4.2 cm3. Aspiration was suggestive of an infective pathology. Excision biopsy of the mass was diagnosed as diffuse large B cell lymphoma with aberrant T cell antigen expression. She received 4 cycles of chemotherapy after which she was lost to follow-up. CONCLUSION: The case presented as a diagnostic dilemma for the pathologist. The predicament lies in classifying it as a B cell lymphoma with an aberrant expression of T cell markers versus a T cell lymphoma with an aberrant B cell marker expression which has a significant implication on the treatment offered. This can be solved by looking at the expression of the B cell specific transcription factors. The key to diagnosis lies in the knowledge of their existence and the application of a panel of markers.
BACKGROUND: Aberrant T cell antigen expression has been well documented in diffuse large B cell lymphomas. However, co-expression of multiple T cell antigens including CD3, which has been considered a specific marker for T cells is extremely rare. Awareness about such aberrant expression is important so as not to misdiagnose or wrongly classify a lymphoma. The aim of this article is to report such a case. CASE PRESENTATION: A 68-year-old postmenopausal lady, diabetic and hypertensive, presented with an axillary lump of one week's duration. There was no other relevant medical history. Ultrasonography revealed multiple hypoechoic cystic lesions varying in size from 3.9 to 4.2 cm3. Aspiration was suggestive of an infective pathology. Excision biopsy of the mass was diagnosed as diffuse large B cell lymphoma with aberrant T cell antigen expression. She received 4 cycles of chemotherapy after which she was lost to follow-up. CONCLUSION: The case presented as a diagnostic dilemma for the pathologist. The predicament lies in classifying it as a B cell lymphoma with an aberrant expression of T cell markers versus a T cell lymphoma with an aberrant B cell marker expression which has a significant implication on the treatment offered. This can be solved by looking at the expression of the B cell specific transcription factors. The key to diagnosis lies in the knowledge of their existence and the application of a panel of markers.
Entities:
Keywords:
Aberrant antigen expression; CD 3; Diffuse large B cell lymphoma
Authors: Jun Wang; Chen Chen; Sean Lau; Ravi I Raghavan; Edward H Rowsell; Jonathan Said; Lawrence M Weiss; Qin Huang Journal: Am J Surg Pathol Date: 2009-04 Impact factor: 6.394
Authors: Jennifer L Oliveira; Karen L Grogg; William R Macon; Ahmet Dogan; Andrew L Feldman Journal: Am J Surg Pathol Date: 2012-09 Impact factor: 6.394
Authors: Nikhil A Sangle; Archana M Agarwal; Kristi J Smock; Matthew O Leavitt; Roger Warnke; David Bahler; Sherrie L Perkins Journal: Appl Immunohistochem Mol Morphol Date: 2011-12
Authors: T Inaba; C Shimazaki; T Sumikuma; A Okano; M Hatsuse; A Okamoto; R Takahashi; E Ashihara; S Hibi; Y Sudo; N Yamagata; S Murakami; K Rin; N Fujita; M Yoshimura; M Nakagawa Journal: Br J Haematol Date: 2000-06 Impact factor: 6.998
Authors: Jeremy C Wallentine; Sherrie L Perkins; Sheryl R Tripp; Richard D Bruggman; Michael G Bayerl Journal: J Pediatr Hematol Oncol Date: 2009-02 Impact factor: 1.289